Afexa Life Sciences Inc.
TSX : CVQ

Afexa Life Sciences Inc.

November 01, 2006 08:00 ET

CV Technologies Inc.: World Science Body Selects COLD-fX'R' Clinical Trial Results for Inclusion in Major Medical Publication

EDMONTON, ALBERTA--(CCNMatthews - Nov. 1, 2006) -

Attention: Health Editors

CV Technologies Inc. (TSX:CVQ), maker of COLD-fX®, today provided an update to the business, scientific and investment community.

Scientific Publications

The Office of Dietary Supplements Division of the National Institutes of Health (NIH) in the U.S. has selected the COLD-fX clinical trial results published last year in the Canadian Medical Association Journal for inclusion in its Annual Bibliography of Significant Advances in Dietary Supplements Research. An international team of 50 scientific reviewers chose it as one of 25 selections drawn from more than 1,000 papers published in 58 of the world's leading peer reviewed medical journals. The NIH, one of the world's foremost medical research centres and an adjunct of the U.S. Department of Health and Human Services, is considered the steward of medical and behavioral research in the United States.

A release from Paul M. Coates, Ph.D., director of the Office of Dietary Supplements says, "Each of the 25 papers reports a study result that is of importance to the field of supplement research as it describes mechanisms by which supplements act to create a health effect or provides a better understanding of the health effects in individuals."

Dr. Coates says, "Each year, the bibliography provides a snapshot of key scientific research published in the field."

CV Technologies Inc. president, CEO & Chief Scientific Officer, Dr. Jacqueline Shan, says, "We are pleased by the recognition given to clinical research on our product, COLD-fX, by this highly regarded body."

Immunological data gleaned from the CMAJ clinical study previously mentioned has been published in this month's issue of the Journal of Clinical Biochemistry and Nutrition. Researchers report that COLD-fX is effective in increasing T-helper and Natural Killer (NK) cell levels in the blood.

Medical Newsletter

A popular medical newsletter Nutrition and Healing endorses COLD-fX in its November issue. The international publication focuses on evidence based natural health products.

Multi-Centre Clinical Trial - Halifax added

Healthy seniors in Halifax will now have the opportunity to join those in Toronto, Vancouver and Edmonton in a national trial designed to investigate the effectiveness of COLD-fX in the prevention of upper respiratory infections in those who have been vaccinated against influenza. The Halifax trial will be led by Dr. Shelly McNeil, MD, Associate Professor of Internal Medicine at Dalhousie University.

Dr. McNeil joins Dr. Gerry Predy, Medical Officer of Health in Edmonton; Dr. Andrew Simor, head of Microbiology at Sunnybrook and Women's College Health Sciences Centre in Toronto and Dr. Janet McElhaney, head of Geriatric Medicine at the University of British Columbia in Vancouver in the trial which was launched in the fall of 2005. The Company decided to extend the trial an additional year because of low recruitment as a result of last year's mild winter.

Dr. McNeil says, "I am impressed by the commitment of CV Technologies to provide high-quality scientific evidence to prove the effectiveness of COLD-fX and am pleased to be able to contribute to this research effort."

Halifax Medical Officer of Health, Dr. Robert Strang says, "The preliminary evidence indicates that this is an effective therapy for the prevention and treatment of colds and flu and can complement vaccinations. We're pleased that Halifax is participating in the process to examine this promising therapy."

About CV Technologies Inc.

CV Technologies, founded in 1992, is a global leader in the development and commercialization of naturally derived, evidence based, natural therapeutics for disease prevention and health maintenance. The Company's lead product - COLD-fX® - strengthens the immune system and is widely used as a leading over the counter remedy (OTC) for preventing and relieving cold and flu infections. In the United States it is marketed as an immune enhancing dietary supplement. COLD-fX®, with its unique and patented mechanism of action was standardized according to the Company's ChemBioPrint (CBP) Process. The CBP process precisely identifies the chemical profile and biological activity of multi-active compounds in evidence-based natural therapeutics. The CBP process also provides a manufacturing protocol that ensures each batch of the final product delivers verifiable and provable health benefits.

This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this discussion, including those comments predicting the timing and/or initiation of clinical trials, whether enrolment in ongoing clinical trials will proceed at an acceptable rate, clinical trial results and associated regulatory clearances, entry and timing of entry into the U.S. market and the potential success of such initiatives. Factors which could cause actual results or events to differ include, but are not limited to: the impact of competition; consumer confidence and spending levels; general economic conditions; interest and currency exchange rates; unseasonable weather patterns; the cost and availability of capital; the cost and availability of grants/funding; product development and the risk that clinical trials may not demonstrate the safety and efficacy required to satisfy the regulatory authorities. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct and that the results, performance or achievements expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company assumes no duty to update this disclosure.

Contact Information